Histamine and Bone Pain Association in Participants With Breast Cancer Metastatic in the Bone
Reason given: Low accruals
Key facts
- Where
- Winston-Salem, United StatesSee the site
Where in United States
- Wake Forest University Health SciencesWinston-Salem, United StatesNo longer taking part
Trial details
- Who runs it
- Wake Forest University Health Sciences
- Trial code
- NCT03529565
- Record updated
- 3 August 2026
- Original description
This trial studies histamine and bone pain association in participants with breast cancer that has spread to the bone. Studying histamine levels in samples of blood from participants with breast cancer in the laboratory may help doctors learn more about reducing cancer bone pain and preventing further bone metastasis.Read full original descriptionShow less
The Role of Histamine in Breast Cancer Bone Pain
This trial studies histamine and bone pain association in participants with breast cancer that has spread to the bone. Studying histamine levels in samples of blood from participants with breast cancer in the laboratory may help doctors learn more about reducing cancer bone pain and preventing further bone metastasis.
Inclusion: Breast cancer patients with radiographic evidence of bone metastases (by plain film, computed tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET] or bone scan) within 8 weeks of registration; Weight bearing sites: pelvis (excluding pubis), femur, sacrum and/or sacroiliac joints, tibia, up to 5 consecutive cervical, thoracic or lumbar vertebral bodies, lumbosacral spine; Non-weight bearing sites: up to 3 consecutive ribs, humerus, fibula, radius +/- ulna, clavicle, sternum, scapula, pubis; Patients with and without pain related to the radiographically documented metastases are eligible for study; Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document.
Exclusion: Pregnant women will be excluded.